As of 2024-12-13, the Relative Valuation of Neogenomics Inc (NEO) is (20.00) USD. This relative valuation is based on P/E multiples. With the latest stock price at 17.90 USD, the upside of Neogenomics Inc based on Relative Valuation is -211.7%.
The range of the Relative Valuation is (19.03) - (20.52) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.4x - 34.9x | 33.3x |
| Forward P/E multiples | 31.3x - 33.9x | 32.8x |
| Fair Price | (19.03) - (20.52) | (20.00) |
| Upside | -206.3% - -214.6% | -211.7% |
| Date | P/E |
| 2024-12-11 | -30.01 |
| 2024-12-10 | -30.44 |
| 2024-12-09 | -29.58 |
| 2024-12-06 | -29.33 |
| 2024-12-05 | -28.39 |
| 2024-12-04 | -29.74 |
| 2024-12-03 | -29.43 |
| 2024-12-02 | -29.73 |
| 2024-11-29 | -29.28 |
| 2024-11-27 | -29.30 |
| 2024-11-26 | -28.37 |
| 2024-11-25 | -27.96 |
| 2024-11-22 | -27.07 |
| 2024-11-21 | -25.42 |
| 2024-11-20 | -25.37 |
| 2024-11-19 | -25.37 |
| 2024-11-18 | -24.79 |
| 2024-11-15 | -24.84 |
| 2024-11-14 | -26.08 |
| 2024-11-13 | -27.13 |
| 2024-11-12 | -26.97 |
| 2024-11-11 | -27.00 |
| 2024-11-08 | -26.04 |
| 2024-11-07 | -26.13 |
| 2024-11-06 | -25.53 |
| 2024-11-05 | -24.66 |
| 2024-11-04 | -23.35 |
| 2024-11-01 | -23.12 |
| 2024-10-31 | -22.44 |
| 2024-10-30 | -22.28 |
| 2024-10-29 | -22.33 |
| 2024-10-28 | -22.26 |
| 2024-10-25 | -21.58 |
| 2024-10-24 | -21.55 |
| 2024-10-23 | -21.58 |
| 2024-10-22 | -21.83 |
| 2024-10-21 | -21.68 |
| 2024-10-18 | -22.39 |
| 2024-10-17 | -22.29 |
| 2024-10-16 | -22.84 |
| 2024-10-15 | -23.17 |
| 2024-10-14 | -22.81 |
| 2024-10-11 | -22.34 |
| 2024-10-10 | -22.36 |
| 2024-10-09 | -21.47 |
| 2024-10-08 | -22.19 |
| 2024-10-07 | -22.76 |
| 2024-10-04 | -23.02 |
| 2024-10-03 | -23.32 |
| 2024-10-02 | -23.68 |